Skip to main content
. Author manuscript; available in PMC: 2024 Dec 1.
Published in final edited form as: Gastroenterology. 2023 Aug 30;165(6):1533–1546.e4. doi: 10.1053/j.gastro.2023.08.034

Table 3.

Comparison between correctly classified versus misclassified CTs in the intramural test subset

CTs with PDA (n=409) Control CTs (n=829)
Correctly classified (n=360) Misclassified (n=49) P-value Correctly classified (n=783) Misclassified (n=46) P-value
Males: Females 1.2:1 1:1 0.83 0.8:1 1.2:1 0.31
Mean age (SD) (years) 66.7 (9.9) 65.4 (10.4) 0.38 55.3 (15.8) 63.9 (14.1) <0.001
Slice thickness (mm) 0.86 0.47
0–1.25 151 (42%) 23 (47%) 277 (35%) 19 (41%)
1.25–3.0 130 (36%) 17 (35%) 488 (62%) 25 (54%)
3.0–5.0 79 (22%) 10 (18%) 18 (2%) 2 (4%)
CT vendor 0.75 0.06
Siemens 210 (58%) 30 (62%) 694 (88%) 37 (80%)
GE 105 (29%) 15 (30%) 67 (9%) 9 (20%)
Toshiba 39 (11%) 3 (6%) 21 (3%) 0 (0%)
Philips 6 (2%) 1 (2%) 1 (0.1%) 0 (0%)
Tumor location 0.14
Head 259 (72%) 33 (68%) .. .. ..
Body 43 (12%) 3 (6%) .. .. ..
Tail 54 (15%) 13 (26%) .. .. ..
Predominantly extrapancreatic 4 (1%) 0 (0%) .. .. ..
Ancillary features
MPD dilation and/or cut off 281 (78%) 22 (45%) <0.01 .. .. ..
CBD dilation and/or cutoff 178 (49%) 18 (37%) 0.13 .. .. ..
Pancreatic atrophy 231 (64%) 22 (45%) 0.01 .. .. ..
Tumor Size (cm) 0.001
Mean (SD) 3.5 (1.3) 2.8 (0.8) .. .. ..
Median 3.3 2.8 .. .. ..
Tumor stage 0.04
1 28 (8%) 7 (14%) .. .. ..
2 252 (70%) 39 (80%) .. .. ..
3 57 (16%) 3 (6%) .. .. ..
4 23 (6%) 0 (0%) .. .. ..
Isodense tumors 71 (20%) 16 (33%) 0.06 .. .. ..